[1]
R. M. Pereira, “Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose”, Clinics, vol. 78, p. 100150, Nov. 2022, doi: 10.1016/j.clinsp.2022.100150.